Gil Van Bokkelen
For more than a decade Gil has been involved in the emerging field of regenerative medicine and cell therapy. Currently he is involved through role as Chairman & CEO at Athersys (where they have multiple clinical stage programs applying a patented and proprietary cell therapy product called MultiStem), and through his involvement with the Alliance for Regenerative Medicine (ARM), a non-profit consortium of over 120 institutions (including large and small companies, patient advocacy groups, disease foundations, clinical and research centers) based in Washington DC, and the National Center for Regenerative Medicine (NCRM) based in Ohio. Athersys is also developing novel treatments for diabetes and obesity, which represent unmet major healthcare challenges.
Gil's primary professional goals are to see healthcare and medicine transformed through the development of safer, more effective, and more cost effective therapies, and to establish Athersys as a leading biopharmaceutical company that has a lasting and transformational impact on medical care.
Gil's primary professional goals are to see healthcare and medicine transformed through the development of safer, more effective, and more cost effective therapies, and to establish Athersys as a leading biopharmaceutical company that has a lasting and transformational impact on medical care.